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Peritoneal lymphomatosis (PL) is a rare presentation of extranodal precursor leukemia/lymphoma. The presentation 
is often non-specific, leading to delayed diagnosis and treatment. In this case, though the preliminary diagnosis was 
established on ascitic fluid cytology, the disease progressed rapidly, leading to demise before initiating chemotherapy. 
Immunophenotyping and molecular studies, performed later, established a diagnosis of de novo B-cell precursor leukemia/
lymphoma with MYC, BCL2 rearrangements (Double-hit lymphoma). MYC, BCL2 rearrangements are rarely reported in 
precursor B-lymphoma/leukemia which carry dismal prognosis. In this report, we illustrate autopsy findings of PL in an 
elderly gentleman who presented with ascites for evaluation. 
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INTRODUCTION
Peritoneal lymphomatosis (PL) is a rare presentation 
of extranodal Non-Hodgkin lymphoma (NHL). Since 
the clinical presentation of PL is non-specific, the 
diagnosis is often delayed. Peritoneal carcinomatosis 
accompanied by malignant ascites is relatively common; 
however, ‘peritoneal lymphomatosis’ is rarely reported 
in the literature.1 Differentiation of PL from other 
morbid entities with similar imaging features such 
as tuberculous peritonitis, peritoneal carcinomatosis, 
and peritoneal mesothelioma is difficult without a 
histological diagnosis.2 In the present genomic era, 
the appropriate immunohistochemical and molecular 
workup of lymphoma is indispensable for guiding 
therapy and prognostic information. The 2016 revised 
World Health Organization (WHO) classification of 
lymphoid neoplasms has included the category of 
high-grade B cell lymphomas (HGBLs) with combined 
MYC and BCL2 and/or BCL6 rearrangements termed 
as double-hit (DH) or triple-hit (TH) respectively.3,4 DH 
is usually reported commonly in diffuse large B-cell 
lymphoma (DLBCL), less frequently in follicular 
lymphomas and rarely in B-lymphoblastic lymphoma/
leukemia (B-LBL).4,5 There is limited information on 
cases of B-LBL with MYC and BCL2 rearrangement. 
In addition, there are cases of HGBL which can express 
Tdt rendering a diagnostic dilemma. Herein, we 
present autopsy findings of an elderly gentleman who 
presented with ascites for evaluation.
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CASE REPORT
A 55-year-old gentleman presented with 
abdominal distension to the gastroenterology 
service. The distension was insidious in onset, along 
with decreased urine output over the last 20 days. 
On examination, the patient had tense ascites 
with bilateral pitting pedal edema. There was no 
history of jaundice, hematemesis, melena, altered 
sensorium, fever, night sweats, or weight loss. 
Ultrasound revealed ascites with mild hepatomegaly 
and hydroureteronephrosis of the right kidney. 
Upper gastrointestinal endoscopy did not reveal any 
varices. Hepatotropic viruses’ markers were negative. 
His renal function tests were deranged. Blood urea 
was 128 mg/dl (reference range [RR]; 15-40mg/dl) 
and serum creatinine was 2.9 mg/dl (RR; 0.6-1.2mg/
dl). The liver function test on admission day was as 
follows: Total bilirubin: 0.4 mg/dl (RR: 0.2 - 1.2 mg/
dl), conjugated bilirubin 0.2 mg/dl (RR: 0 - 0.3 mg/dl); 
AST: 37 (RR: 2-40 U/L) ALT: 32 (RR: 2-41 U/L) alkaline 
phosphatase: 62 IU/L (RR; 44-147 IU/L). However, 
terminally (3 days after admission), the AST/ALT/
ALP were 408/90/2042 IU, respectively. Abdominal 
ultrasonography did not reveal features of acute Budd-
Chiari syndrome such as thickened walls, intraluminal 
echogenicity, and compressed hepatic veins or inferior 
vena cava.
The ascitic fluid analysis revealed a high serum 
ascites albumin gradient (SAAG) ascites (1.2 g/dl). 
Initial ascitic tap showed sheets of polymorphs, and the 
subsequent cytology showed numerous intermediate 
size lymphoid cells with a high nuclear/cytoplasmic 
ratio. Immunocytochemistry showed lymphoid cells 
strongly positive for CD45, CD10, Tdt, and C-MYC. 
Focal positivity for CD20, CD19, CD79a was seen in 
these atypical lymphoid cells, and a working diagnosis 
of B-cell lymphoblastic lymphoma/leukemia was kept. 
Peripheral blood smear did not show blasts. CSF tap 
did not show atypical cell infiltration. CECT abdomen 
and PET-CT scan were deferred due to deranged renal 
function test.
Differentials for ascites were considered based on 
the serum-ascites-albumin gradient (SAAG). Cutoff of 
>1.1mg/dl is considered as high SAAG, which includes 
conditions like cirrhosis, heart failure, Budd-Chiari 
syndrome, sinusoidal obstruction syndrome. Low SAAG 
includes malignancy, infection, and pancreatitis, 
among others. The ultrasonography, endoscopy, 
and hepatic viral markers were negative for cirrhosis, 
varices, and viral hepatitis, respectively; enabling a 
rapid ascitic fluid malignant cytology analysis. It is 
interesting to note that despite being a case of PL, this 
case showed high SAAG ascites.
Since the initial two ascitic fluid taps showed 
neutrophils, the patient was empirically started on IV 
cefoperazone-sulbactum, oral acyclovir, oral fluconazole 
and twice weekly cotrimoxazole. Low molecular 
heparin was given as deep venous thrombosis (DVT) 
prophylaxis. Fluconazole and cotrimoxazole were 
withheld later in view of worsening liver function tests 
(LFT), and acyclovir was also stopped in view of renal 
failure. Pre-emptive steroids and chemotherapy could 
not be started because of the poor general status of 
the patient.
The patient’s renal and liver function deteriorated, 
and he had a sudden cardiac arrest and could not 
be revived despite resuscitation efforts. A complete 
autopsy was performed after obtaining informed 
written consent from the patient’s next of kin.
AUTOPSY FINDINGS
The peritoneal cavity yielded 2 liters of straw-
colored fluid. The mesentery and the omentum 
appeared thick and nodular, forming adhesions to 
the intestinal wall (Figure 1A). Either side of the 
diaphragm showed similar greyish white deposits. 
The liver weighed 2300 g (RR;1330-2100g) and was 
diffusely enlarged. The porta hepatis showed a greyish 
white mass measuring 4x3x2cm infiltrating the hepatic 
parenchyma (Figure 1B). This tumor also infiltrated the 
pancreas, stomach, the serosal surfaces of the small 
and large intestine and right kidney. A similar deposit 
was seen in the periadrenal fat. No significant lymph 
node enlargement was noted. The heart and brain 
were grossly and microscopically unremarkable.
The microscopy revealed relatively uniform-
appearing atypical lymphoid cells with blastoid 
morphology. These cel ls were infi ltrating the 
peritoneum, porta hepatis, renal pelvis, serosa and 
mucosa of the gastrointestinal tract (Figure 1C). 
The cells were intermediate-sized with round to 
convoluted nuclei with condensed nuclear chromatin, 
indistinct nucleoli, and scanty cytoplasm. These cells 
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were positive for CD45, CD20, CD10, TdT, CD99 (dot-
like), Bcl2 (>70%), and C-MYC (>40%) while they were 
negative for CD3, CD5, CD34, CD23, Bcl6, Mum1, 
Cyclin D1 and SOX11 (Figure 1D, 2A, 2B, 2C and 2D).
Immunophenotypic diagnosis of B-lymphoblastic 
lymphoma/leukemia was considered. The fluorescence 
in-s i tu hybr id izat ion (F ISH)  was pos i t ive for 
BCL2 rearrangement (18q21) (Vysis LSI BCL2 Dual 
Color Break Apart Rearrangement Probe) (Figure 3A) 
and CMYC-IGH fusion (IGH/MYC/CEP 8 Tri-Color Dual 
Fusion Probe) (Figure 3B).
However, FISH was negative for BCL6, BCR-ABL-1, 
KMT2A translocation, ETV6-RUNX1 translocation, 
and chromosome-21 amplification. Real-time PCR 
was negative for CRLF2 overexpression. Copy number 
abnormalities revealed homozygous deletions of Exon 
2 & 4 of CDKN2A and Exon 2 of CDKNA2B (Figure 4). 
Bone marrow biopsy was normocellular with adequate 
representation of all marrow elements. There was no 
infiltration by lymphoma or involvement by leukemic 
process. The peripancreatic and peribiliary lymph nodes 
did not show the lymphomatous process. The autopsy 
did not reveal features of hepatic venous outflow 
obstruction. There was no evidence of pulmonary 
thromboembolism. There was focal subpleural 
infiltration through the diaphragm (direct extension) 
by lymphoma on the right side.
DISCUSSION
Non-Hodgkin lymphoma presents primarily as an 
extranodal disease in 25-40% of cases.6 It can affect 
organs and sites such as the biliary tree, liver, spleen, 
gastrointestinal tract, adrenals, peritoneal cavity, 
Figure 1. A – Gross view of the abdominal cavity showing diffuse nodular thickening of the peritoneum; B – Gross 
view of the liver’s cut surface showing infiltration of the tumor (yellow arrow); C and D – Photomicrographs of the 
tumor; C – Tumor cells infiltrating the gastric antral glands (H&E, 200X); D – Photomicrograph of the omentum 
showing tumor cells diffusely positive for CD20 (200X).
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Figure 2. Photomicrograph of the tumor showing in A – Bcl2 positive (200X); B – Tdt positive (200X); C – positive 
c-myc (200X).
Figure 3. A – BCL2 Dual Color break-apart rearrangement probe showing one orange, one green, and one orange/
green fusion (1O1G1F) signal pattern indicating BCL2 rearrangement (Pink arrows indicating split signals); B – IGH/
MYC/CEP 8 Tri-Color Dual Fusion Probe hybridized to an abnormal nucleus showing one fusion (1F) one orange (01) 
one green (G1) and 2A signal pattern indicating CMYC-IGH fusion (yellow arrow indicating fused signal).
among others. Peritoneal surfaces can be involved by 
malignancies from all three cell-lineages: epithelial 
(carcinomatosis), mesenchymal (sarcomatosis), and 
lymphoid (lymphomatosis). Peritoneal lymphomatosis 
(PL) is defined as the “intraperitoneal spread of 
lymphoma”. It can be seen either in association with 
a primary visceral site of involvement, or without any 
visceral involvement.7,8 The route of dissemination is 
postulated to be through visceral peritoneal surfaces, 
gastrocolic ligament, and transverse mesocolon. PL is 
an exceptional clinical scenario, which is frequently 
associated with primary gastrointestinal NHL (high 
grade) and is radiologically identical to peritoneal 
carcinomatosis. Diffuse large B-cell lymphoma (DLBCL) 
is the most common lymphoma presenting as PL. 
Multiple patterns of PL include infiltrative mass, distinct 
nodular, and ascites.8 In the present case, there was 
a diffusely infiltrative mass presenting with ascites.
Based on the immunohistochemical and molecular 
workup, the present case was a de novo B-LBL 
with MYC, BCL2 rearrangements. Double-hit/triple-
hit lymphoma is characterized by MYC (8q24) 
rearrangement in combination with a BCL2 (18q21) 
and/ or a BCL6 (3q27) rearrangement.9,10 Double-hit 
lymphomas (DHL) are rare and represent 4-8% of all 
diffuse large B-cell lymphomas. They tend to occur 
in extranodal sites. Four morphological variants have 
been described in DHL; DLBCL-like, features previously 
designated as B-cell lymphoma unclassifiable (BCL-U) 
in 2008 WHO classification, Burkitt lymphoma-like and 
lymphoblastic lymphoma-like .4,11
There are few case reports of B-ALL with double 
hit genetics reported in literature.12,13 In most of those 
cases, the blasts were L3 type (French-American-British 
classification) and majority of them had acute leukemia 
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like presentation. Few of the cases had a leukemic 
transformation from DLBCL. Conversely, on the other 
end of the spectrum, there can be acute lymphoblastic 
leukemia-like high grade B-cell lymphoma with MYC 
and BCL2 and/or BCL6 rearrangement lacking Tdt 
and other immaturity markers.14 Ok et al.15 described 
a series of 13 cases of high-grade B-cell lymphomas 
with TdT expression grouped into three categories. 
These included cases of de novo high-grade B-cell 
lymphoma with Tdt expression as well as blastic 
transformation of a low grade B-cell lymphoma which 
acquired Tdt during relapse. Features that favoured 
HGBL over LBL were positivity for BCL6 and monotypic 
surface immunoglobulin. All the cases showed dismal 
outcome, despite appropriate therapy.
In the present case, copy number analysis revealed 
homozygous deletions of Exon 2 & 4 of CDKN2A and 
Exon 2 of CDKNA2B gene. These genes are involved in 
cell cycle regulation and homozygous deletion carries 
poor prognosis in ALL.16
There are two reported cases of double-
hit lymphoma expressing Tdt and presenting as 
ascites.17,18 Unlike ours, one case was a transformation 
from follicular lymphoma, and the other had involvement 
of the pancreas primarily. Primary effusion lymphoma 
(PEL) driven by HHV-8 is another differential. PEL cells 
typically display a “null” lymphocyte phenotype, 
i.e., CD45 is expressed, but routine B-cell (including 
surface and cytoplasmic immunoglobulin, CD19, 
CD20, CD79a) and T-cell (CD3, CD4, CD8) markers 
are absent. Instead, various markers of lymphocyte 
activation (CD30, CD38, CD71, human leukocyte 
antigen DR) and plasma cell differentiation (CD138) 
are usually displayed.19 Peritoneal lymphomatosis 
is treated non-surgically and often shows dramatic 
improvement with chemotherapy. Therefore, early and 
precise diagnosis is of utmost importance. However, 
PL with double-hit phenotype has a belligerent course 
and a poor outcome despite appropriate treatment.20
Double-hit genetics (MYC, BCL2 rearrangement) 
have inferior outcome with standard chemotherapy. 
This case highlights that double hit genetics can 
be seen in B-precursor lymphoma/leukemia and a 
separate classification of this entity may be beneficial 
for prognostication and may facilitate further research 
and design the novel therapeutic approaches such as 
MYC and BCL2 inhibitors.
Figure 4. Multiplex ligation-dependent probe amplification revealed homozygous deletions of Exon 2 & 4 of 
CDKN2A and Exon 2 of CDKNA2B.
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CONCLUSIONS
• There should be early institution of empirical treatment 
while awaiting diagnostic results as it has an aggressive 
course and poor outcome;
• De novo double-hit B-cell precursor leukemia/lymphoma 
needs separate recognition for facilitating further 
research and targeted therapy.
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